Visus raises $20M ahead of data drop on rival to AbbVie prospect

Visus Therapeutics has raised a further $20 million as it closes in on the release of midphase data on a potential treatment for age-related long-sightedness. The financing comes on the heels of phase 3 data on rival candidates in development at AbbVie and Eyenovia.